Pharmacological Considerations during Percutaneous Treatment of Heart Failure

• Published in: Current pharmaceutical design Vol. 30; no. 8; p. 565
• Main Authors: Sorolla-Romero, Jose Antonio, Navarrete-Navarro, Javier, Martinez-Sole, Julia, Garcia, Hector M Garcia, Diez-Gil, Jose Luis, Martinez-Dolz, Luis, Sanz-Sanchez, Jorge
• Format: Journal Article
• Language: English
• Published: United Arab Emirates 01.01.2024
• Subjects: Heart Failure - drug therapy; Heart Failure - therapy; Humans; ECMO; Heart failure; TriClip; MitraClip; Impella; cardiogenic shock; TandemHeart; interventional cardiology
• ISSN: 1873-4286
• DOI: 10.2174/0113816128284131240209113009

Heart Failure (HF) remains a global health challenge, marked by its widespread prevalence and substantial resource utilization. Although the prognosis has improved in recent decades due to the treatments implemented, it continues to generate high morbidity and mortality in the medium to long term. Interventional cardiology has emerged as a crucial player in HF management, offering a diverse array of percutaneous treatments for both acute and chronic HF. This article aimed to provide a comprehensive review of the role of percutaneous interventions in HF patients, with a primary focus on key features, clinical effectiveness, and safety outcomes. Despite the growing utilization of these interventions, there remain critical gaps in the existing body of evidence. Consequently, the need for high-quality randomized clinical trials and extensive international registries is emphasized to shed light on the specific patient populations and clinical scenarios that stand to benefit most from these innovative devices.